Titlebook: Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins; Ulf Grawunder,Stefan Barth Book 2017 Springer International Publishing A

VALID

,Substance P–Saporin for the Treatment of Intractable Pain,ly links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing. We review the history of SP-SAP and rel

champaign

Recombinant Immunotoxins for Chronic Inflammatory Disease,c inflammatory disorders like atopic dermatitis, rheumatoid arthritis, and diabetic ulcers, as many of these are strongly age related. There is thus an increasing demand to develop better therapeutic strategies to manage and cure chronic diseases. In many of these diseases, the trigger for onset of

騎師

BL22: A Milestone in Targeting CD22,xotoxin. The antibody fragment that binds to the target cell is internalized along with the toxin, and the toxin fragment is transported to the cytosol where it catalytically kills the cell. Preclinical development showed significant cytotoxicity and antitumor activity toward CD22+ leukemia and lymp

人充滿活力

BAN

行業(yè)

BUCK

Muscularis

2296-6056 will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology..978-3-319-83609-6978-3-319-46877-8Series ISSN 2296-6056 Series E-ISSN 2296-6064

FECK

雪白